Friday, October 31, 2014

Top Life Sciences Stocks To Own For 2014

Miami, Fl.-based Opko Health (NYSE: OPK  ) took a 10% stake in Russian peer pharmaceutical firm OAO Pharmsynthez, Opko announced Thursday.

Like the name sounds, Pharmsynthez is a drugmaker and, in fact, the only life sciences company currently trading on the Moscow Stock Exchange. (The "OAO" simply refers to the Russian words for "joint stock company," the Russian designation for a public corporation). It manufactures and sells branded pharmaceutical products, primarily in Russia and the Baltics.

Opko described its stake-purchase as part of a $60 million, two-stage financing project, whereby Russian state-owned corporation Russian Corporation of Nanotechnologies first invested $26.1 million in Pharmsynthez, followed by Opko's larger investment.

Going forward, Opko plans to partner with Pharmsynthez in the development and marketing of several of its own products for sale in Russia and other East European countries, specifically:

CTAP101 Capsules, a vitamin D prohormone to treat secondary hyperparathyroidism �in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency several diagnostic products utilizing OPKO's point of care platform Opko's "4Kscore," panel of kallikrein biomarkers used in the detection of prostate cancer

The companies will also collaborate on R&D projects.

Hot Trucking Companies To Own In Right Now: Inc (SNET), Inc., incorporated in 1994, was involved in developing and deploying merchandise-sourcing solutions for the retail industry prior to its operating assets sale in March 2004. The Company's Internet-based, hosted solutions for the pre-order phase of business-to-business merchandise procurement enabled retailers to organize, automate and reduce the cost of their merchandise-sourcing activities by locating and connecting directly with their retail merchandise suppliers around the globe. Its solution, branded MySourcingCenter, provided an online location for search, display and comparison functions, and linked and managed the data and communications between retailers and merchandise suppliers in industry-specific private environments, organizing and automating sourcing or pre-order merchandise procurement activities over the Internet. The majority of the Company's revenue through the fiscal years ended March 31, 2001 (fiscal 2001) to 2003 (fiscal 2003) was generated from a contract entered into, in March 2000, with Carrefour S.A. After completion of the Carrefour agreement,, Inc. was unable to procure additional contracts to replace the revenue generated by the Carrefour agreement. sold its operating assets and intellectual property, and its two customer contracts in two separate transactions, in March 2004, (collectively, the operating assets sale), and ceased its operating business at that time. Its fixed assets, software, intellectual property and customer contracts related to Internet-based merchandise sourcing solution were sold to a third party in Europe. The Company's list of potential customers and certain Lotus Notes templates related to its professional services business were sold to a separate foreign company.

Prior to the operating assets sale in March 2004, the Company also performed professional services that accounted for the majority of its revenue since fiscal 2001. Its professional services enabled customers to ! implement Internet-based electronic negotiations (eSourcing) solutions.'s service offering was buyer auction programs, which encompassed assessment, savings delivery and training aimed at optimizing auction processes within the buying organization.

MySourcingCenter is an online sourcing solution for finding, displaying, comparing and negotiating the purchase of products. The Company provided customers with a turnkey solution, including project management for buyer rollout and both online and global helpdesk support for buyers and suppliers. Reporting and forms were standardized for suppliers and standard forms were also available for retailers. In addition, mapped standard supplier data to any forms specification the retailer may have had, providing a customized display to meet retailer requirements. All of the underlying software resided outside of customer firewalls in a third party co-location facility.

The Company's only customer for MySourcingCenter was the international purchasing department of France-based Leroy Merlin. It also signed a contract with a United States-based customer, for which initial planning had occurred prior to the operating assets sale in March 2004. provided professional services in the area of Internet-based, pre-order merchandise procurement. It assisted retailers in the conduct of online real-time negotiation events and trained buying organizations to become autonomous in conducting such events. Related to the Company's Internet solution, it provided project management for retailer implementations of MySourcingCenter. provided services to Carrefour, from April 2000, through mid-fiscal 2004, under a three-year contract. This contract provided the majority of the Company's revenues during the prior three fiscal years. It also provided services to the WorldWide Retail Exchange and certain of its members. One such contract provided about one-third of its services revenue ! during fi! scal year 2004. The Company's professional services customers included Carrefour, under the Carrefour contract, and members of several industry exchanges, including the WorldWide Retail Exchange, a retail industry exchange with 60 members around the globe, and CPGmarkets, an exchange for manufacturers of consumer packaged goods, whose members are in Europe.

Advisors' Opinion:
  • [By Peter Graham]

    Small cap stocks IDGlobal Corp (OTCMKTS: IDGC), Embarr Downs Inc (OTCMKTS: EMBR) and, Inc (OTCMKTS: SNET) have been getting some extra attention in various investment newsletters or investor alerts lately as at least two of these stocks have been the subject of paid promotions or other types of investor relations activities. Of course, there is nothing wrong with properly disclosed promotions or investor relations activities. But just how hot are these two small cap stocks? Here is a closer look and a quick reality check:

Top Life Sciences Stocks To Own For 2014: Green Automotive Co (GACR)

Green Automotive Company, incorporated on November 15, 1996, is a vehicle design, engineering, manufacturing and distribution company. The Company also provides after sales program. It possesses a portfolio of businesses and is active in three main market segments: Cutting edge technology development, engineering and design with a focus on zero and low emission vehicle solutions; Manufacturing and customization of vehicles for markets with the potential to be converted into low emission or electric vehicles, such as shuttle buses, taxis, commercial vehicles, and After sales services for electric or low emission vehicles, including servicing and repair. On December 14, 2012, the Company closed its merger with Matter of Time I Co. As per the merger agreement, Matter of Time I Co. dissolved into and became a part of Green Automotive Company, with Green Automotive Company being the surviving corporation. In January 2014, Green Automotive Co Inc acquired a 21.63% interest in Viridian Motor Corp Inc.

The Company's two divisions servicing the three segments are Liberty Electric Cars Ltd and Newport Coachworks Inc. Liberty Electric Cars Ltd designs and develops EV technologies for use in its own converted vehicles and for sale to original equipment manufacturers (OEM��) for incorporation into its production. In addition, it provides an aftermarket program for electric vehicle users to ensure the longevity of their vehicles. Newport Coachworks Inc. specializes in building shuttle buses, running on a variety of energy sources from petrol and diesel though to compressed natural gas (CNG).

The Company competes with Zytec, AMPD, Siemens, Tiffany, Krystal, Ford, and General Motors, Cummins and Freightliner.

Advisors' Opinion:
  • [By Bryan Murphy]

    While Green Automotive Co. (OTCMKTS:GACR) is certainly no Nissan Motor Co., Ltd. (OTCMKTS:NSANY) or Bayerische Motoren Werke AG (FRA:BMW) (better known as BMW)� in terms of size or notoriety, the two larger car companies certainly seem to be validating the work that GACR is doing. Both Nissan and BMW are betting big on electric vehicles, partly because they want to, and partly because they have to. Either way, Green Automotive is just as capable of tapping into this EV megatrend as its bigger and more established brothers are.

Top Life Sciences Stocks To Own For 2014: ENI S.p.A. (E)

Eni SpA, an integrated energy company, engages in the exploration, production, transportation, transformation, and marketing of oil and natural gas. The company also involves in the production and sale of electricity; refining and marketing of petroleum products; and production and sale of petrochemical products and hydrocarbons. In addition, it engages in the offshore and onshore hydrocarbon field construction. Further, the company offers offshore and onshore drilling, and offshore design and engineering services for oil and gas companies. It has a strategic partnership with Gazprom for the joint development of projects in the upstream oil and gas markets. Eni SpA operates in Europe, Africa, Asia and Oceania, and the Americas. The company was founded in 1953 and is headquartered in Rome, Italy with an additional office in San Donato Milanese, Italy.

Advisors' Opinion:
  • [By Fede Zaldua]

    Eni (E) is an authentic cash cow for its shareholders. I believe the company will be able to sustain a greater than 6% cash dividend yield in 2014 even when the company's estimated 2015 free cash flow (FCF) yield is at just 4%. Asset sales as well as high oil prices should help the company meet its capex requirements and to continue giving back cash to shareholders through dividends. The recent sale of its stake in Sever Energia to the Novatek-GazpromNeft Joint Venture represents a clear hint into the company's strategy. After all, Eni's portfolio has several high quality disposal candidates which could attract the industry's interest – the first disposal candidate that comes to my mind is the remaining 8% stake Eni owns in Galp. The Italian oil and gas leader, which is held by Tom Gayner, sells for 12.5 times 2014 earnings and 5.5 times EV/EBITDAX.  

  • [By Dan Caplinger]

    Much of the reason for Statoil's weakness over the past year comes from a simple fact of geography. Investors have been extremely nervous about instability in the eurozone, and even though oil giants including France's Total (NYSE: TOT  ) , Italy's Eni (NYSE: E  ) , and Norway's Statoil all own energy properties located around the world, their shares have nevertheless traded as though they were overly exposed to their home markets. Moreover, Norway is among the most stable of Europe's national economies, making the cheap valuations even more ridiculous.

  • [By Sarfaraz A. Khan]

    Second, most of the unexplored and lucrative areas lie in the Middle East and Africa, a region which is known for its unstable business environment. For instance, Mozambique is home to enormous gas reserves and has been going on a path to prosperity over the last eight years, which is evident in its 7% GDP growth rates. Leading oil companies, such as Eni SpA (E) and Anadarko Petroleum (APC) have billions at stake in the country. However, the sudden termination of a peace deal by a rebel group recently has raised question marks over the country�� ability to attract investment.

  • [By Sean Williams]

    Despite operating around the globe, many of Chevron's assets are well-protected from political unrest or violence. The same can't be said for Italian-based Eni (NYSE: E  ) which saw a good chunk of its oil production come under serious pressure in 2011 because of civil unrest and an eventual regime change in Libya. At the time, 14% of Eni's daily production ��nearly 250,000 barrels ��came from Libya and it maintained quite a few other undeveloped assets in the country. Eni's prospects have since improved, but other oil and gas companies deal with the similar potential for unrest on a daily basis.

Top Life Sciences Stocks To Own For 2014: Dynavax Technologies Corporation(DVAX)

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The company's lead product candidate includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine designed to provide protection with fewer doses than current licensed vaccines. It also develops Universal Flu vaccine, a Phase 1b clinical trial vaccine for influenza prevention; SD-101, a Phase Ib clinical trial hepatitis C therapy; DV-601, a Phase Ib clinical trial hepatitis B therapy; AZD1419, a preclinical asthma therapy; and DV1179, a Phase 1 trial autoimmune and inflammatory disease therapy. Dynavax Technologies Corporation has strategic alliance with GlaxoSmithKline plc to discover, develop, and commercialize DV1179 and other endosomal toll-like receptor inhibitors for diseases, such as lupus, psoriasis, and rheumatoid arthritis; and develop a TLR8 inhibitor for the treatment of multiple autoimmune and i nflammatory diseases, as well as has research and license agreement with AstraZeneca to discover and develop TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was founded in 1996 and is based in Berkeley, California.

Advisors' Opinion:
  • [By Holly LaFon]

    Steven Cohen, George Soros and John Paulson are three of the most formidable investors alive today. All three of them added to one of their major holdings so far in 2012. Steven Cohen of SAC Capital Advisors added Dynavax Tech Cp (DVAX), George Soros of Soros Fund Management LLC added Acacia Research (ACTG) and John Paulson of Paulson & Co. added Novagold Resources (NG).

  • [By Keith Speights]

    Dynavax (NASDAQ: DVAX  ) is a good case in point. The company's Heplisav hepatitis B vaccine looked good in clinical trials when compared to the leading vaccine on the market. Dynavax thought that the safety profile for Heplisav also compared favorably. The Food and Drug Administration even told the company that it could expand its Biologic License Application, or BLA, to include a wider age range of adults than originally planned.

Top Life Sciences Stocks To Own For 2014: DARA Biosciences Inc.(DARA)

DARA BioSciences, Inc., a development stage biopharmaceutical company, engages in the development and commercialization of oncology treatment and supportive care pharmaceutical products in the United Sates. Its products include Soltamox for the treatment of breast cancer; Gemcitabine for first-line therapy for ovarian, breast, lung and pancreatic cancers; and other cancer support therapeutics, as well as generic sterile injectable cytotoxic products. Its drug development programs include KRN5500, a non-narcotic/non-opioid that has completed Phase IIa clinical trial for the treatment of neuropathic pain in cancer patients; and DB959, which has completed a Phase I study for the treatment of metabolic diseases, including type 2 diabetes and dyslipidemia. The company?s pre-clinical drug candidate includes DB900 PPAR gamma/alpha/delta agonists for development in metabolic and inflammatory diseases; DB160, DPPIV enzyme inhibitors with applications in diabetes, stem cell transpl antation, and cancer therapy; and DB200, Carnitine palmitoyltransferase-1 for skin diseases, including psoriasis. DARA BioSciences, Inc. was incorporated in 2002 and is headquartered in Raleigh, North Carolina.

Advisors' Opinion:
  • [By Bryan Murphy]

    Without knowing the whole story, it would be easy to dismiss the big 9% jump from DARA Biosciences Inc. (NASDAQ:DARA) today as nothing more than a little volatility.... bullishness that wasn't destined to linger, especially considering how ugly the market turned in Monday's trading. As is always the case, though, with DARA, there's more to the story. Today's move may well be the official beginning of a much bigger, trade-worthy rally.

  • [By John Kell and Lauren Pollock var popups = dojo.query(".socialByline .popC"); ]

    Dara Biosciences Inc.(DARA) signed a Medicare Part D prescription drug reimbursement agreement with Wellcare Health Plans Inc.(WCG), providing its Soltamox breast-cancer drug with access to the managed-care company’s extensive network. The pharmaceutical company’s shares rose 19% to $3.45 premarket.

  • [By Lisa Levin]

    DARA BioSciences (NASDAQ: DARA) shares fell 15.02% to touch a new 52-week low of $1.81. DARA BioSciences' trailing-twelve-month ROA is -66.74%.

    LCNB (NASDAQ: LCNB) shares touched a new 52-week low of $16.57. LCNB shares have dropped 4.80% over the past 52 weeks, while the S&P 500 index has gained 18.57% in the same period.

Top Life Sciences Stocks To Own For 2014: NEC Corp (NIPNF)

NEC Corporation is a diversified company. The Information Technology (IT) Solution segment provides system integration, supporting, outsourcing and cloud services, servers, mainframes, super computers, wireless access devices and software. Carrier Network segment provides backbone network system, network access and operation support system, among others. Social Infrastructure segment provides broadcasting video system, control system, transportation and public system, fire and disaster prevention system, and others. Personal Solution segment provides smart phones, cellular phones, corporate computers, tablet terminals, mobile and wireless routers, and Internet service and display solution. The Others segment provides smart energy solution, electronic components and lighting fixtures. On October 1, 2013, it transferred 45% stake in NEC TOPPAN CIRCUIT SOLUTIONS, INC. to KYOCERA CORP, and sold all shares in NEC Magnus Communications Ltd. to NEC Networks & System Integration Corporation. Advisors' Opinion:

    LOS ANGELES (MarketWatch) -- Japanese stocks slipped early Monday, with the Nikkei Stock Average (JP:NIK) down 0.1% at 14,298.17, and the Topix dropping 0.4%. Singapore-traded lead futures for the Nikkei Average had suggested a 0.8% gain for the index, but the indicator fell after the Cabinet Office reported fourth-quarter economic growth of 0.3%, flat from the previous quarter and below expectations in separate Reuters and Wall Street Journal/Nikkei surveys. The disappointing economic data also pushed the yen higher, weighing on some exporters, with Panasonic Corp. (JP:6752) (PCRFF) down 1.8%, NEC Corp. (JP:6701) (NIPNF) off 1.3%, and Sony Corp. (JP:6758) (SNE) down 0.7% after S&P downgraded the firm's credit rating to BBB- from BBB with a negative outlook. Shares of Internet retailer Rakuten Inc. (JP:4755) (RKUNF) dropped 12% after announcing plans to buy online messaging and telecom firm Viber Media Inc. for $900 million as well as posting below-consensus full-year profit. Banks were broadly lower, with Mizuho Financial Group Inc. (JP:8411) (MFG) off 1% and Sumitomo Mitsui Financial Group Inc. (JP:8316) (SMFG) off 1.1%, though Daiwa Securities Group Inc. (JP:8601)


    LOS ANGELES (MarketWatch) -- Japan's Nikkei Average (JP:NIK) traded 0.5% higher in the early minutes Tuesday, extending the previous day's 0.9% advance, with the market getting some support from overnight gains for U.S. shares and a slightly weaker yen (dollar at 楼101.56 vs. 楼101.40 at Monday's open). Among the gainers, Toshiba Corp. (JP:6502) (TOSYY) rose 1.7%, Hitachi Ltd. (JP:6501) (HTHIF) gained 1.5%, NEC Corp. (JP:6701) (NIPNF) improved by 2.5%, Bridgestone Corp. (JP:5108) (BRDCF) added 2.7% to extend gains over the past couple weeks following the company's purchase of U.S.-based Masthead Industries, and Mitsubishi Heavy Industries Ltd. (JP:7011) (MHVYF) traded 1.1% higher as a Wall Street Journal report said the industrial major's Mitsubishi Aircraft unit had reached a tentative deal to sell 40 jets for the planned revival of defunct U.S. carrier Eastern Air Lines Group Inc. Auto makers were firmer as well, with Nissan Motor Co. (JP:7201) (NSANY) up 1.3%, Toyota Motor Corp. (JP:7203) (TM) up 0.5%, and Honda Motor Co. (JP:7267)

No comments:

Post a Comment